Caribou Biosciences (CRBU) Income from Continuing Operations (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Income from Continuing Operations of 28109000.0 for Q1 2026, up 34.68% year-over-year from 20871132.57 in Q1 2025, and up 2.77% quarter-over-quarter from 28909000.0 in Q4 2025.
Caribou Biosciences (CRBU) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Income from Continuing Operations for 7 consecutive years, with 28109000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 34.68% year-over-year to 28109000.0; the TTM figure through Mar 2026 stood at 137157000.0 (up 36.51% YoY), while the FY2025 annual figure was 148125000.0, up 0.66% from the prior year.
- Income from Continuing Operations improved to 28109000.0 in Q1 2026 per CRBU's latest filing, from 28909000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 22678000.0 in Q1 2022 and bottomed at 87360000.0 in Q1 2024.
- Historically, Income from Continuing Operations has averaged 46902117.65 across 5 years, with a median of 40307000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 431.74% — and 2025, when it soared 57.42%.
- Caribou Biosciences' Income from Continuing Operations stood at 31075000.0 in 2022, then declined by 20.89% to 37566000.0 in 2023, then fell by 7.3% to 40307000.0 in 2024, then grew by 28.28% to 28909000.0 in 2025, then rose by 2.77% to 28109000.0 in 2026.
- Business Quant data shows CRBU's Income from Continuing Operations at 28109000.0 in Q1 2026, 28909000.0 in Q4 2025, and 32398000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - | -25.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.30 Mn |
| Mar 31, 2026 | -28.11 Mn |
| Dec 31, 2025 | -28.91 Mn |
| Sep 30, 2025 | -32.40 Mn |
| Jun 30, 2025 | -47.74 Mn |
| Mar 31, 2025 | -43.03 Mn |
| Dec 31, 2024 | -40.31 Mn |
| Sep 30, 2024 | -76.10 Mn |
| Jun 30, 2024 | -56.59 Mn |
| Mar 31, 2024 | -87.36 Mn |
| Dec 31, 2023 | -37.57 Mn |
| Sep 30, 2023 | -29.88 Mn |
| Jun 30, 2023 | -76.67 Mn |
| Mar 31, 2023 | -31.42 Mn |
| Dec 31, 2022 | -31.08 Mn |
| Sep 30, 2022 | -51.42 Mn |
| Jun 30, 2022 | -76.10 Mn |
| Mar 31, 2022 | -22.68 Mn |
| Dec 31, 2021 | -18.48 Mn |
| Sep 30, 2021 | -20.97 Mn |